Glycolytic Regulatory Enzyme PFKFB3 As a Prognostic and Tumor Microenvironment Biomarker in Human Cancers

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2023 May 30

PMID 37253634

Authors

Qingen Da

Lei Huang

Can Huang

Zee Chen

Zhitong Jiang

Fang Huang

Tao Shen

Lu Sun

Zilong Yan

Xiaoqiang Ye

Jing Yi

Yu Huang

Jingjing Da

Mingming Ren

Jikui Liu

Tao Wang

Zhen Han

Kunfu Ouyang

Affiliations

Soon will be listed here.

Abstract

The 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFK-2/FBPase-2, PFKFB3) is a glycolysis regulatory enzyme and plays a key role in oncogenesis of several cancers. However, the systematic study of crosstalk between PFKFB3 and Tumor microenvironment (TME) in pan-cancer has less been examined. In this study, we conducted a comprehensive analysis of the relationship between expression, patient prognostic, Tumor mutational burden (TMB), Microsatellite instability (MSI), DNA mismatch repair (MMR), and especially TME, including immune infiltration, immune regulator, and immune checkpoint, across 33 types of tumors using datasets of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). We found that expression was significantly correlated with patient prognostic and TME factors in various tumors. Moreover, we confirmed that PFKFB3 was an independent prognostic factor for kidney renal papillary cell carcinoma (KIRP), and established a risk prognostic model based on the expression of as a clinical risk factor, which has a good predictive ability. Our study indicated that PFKFB3 is a potent regulatory factor for TME and has the potential to be a valuable prognostic biomarker in human tumor therapy.

Citing Articles

PFKFB3 Connects Glycolytic Metabolism with Endothelial Dysfunction in Human and Rodent Obesity.

Batori R, Bordan Z, Padgett C, Huo Y, Chen F, Atawia R Antioxidants (Basel). 2025; 14(2).

PMID: 40002359 PMC: 11851787. DOI: 10.3390/antiox14020172.

Impact of glycolysis enzymes and metabolites in regulating DNA damage repair in tumorigenesis and therapy.

Sun F, Li W, Du R, Liu M, Cheng Y, Ma J Cell Commun Signal. 2025; 23(1):44.

PMID: 39849559 PMC: 11760674. DOI: 10.1186/s12964-025-02047-9.

Analyzing the impact of metabolism on immune cells in tumor microenvironment to promote the development of immunotherapy.

Long Y, Shi H, He Y, Qi X Front Immunol. 2024; 14:1307228.

PMID: 38264667 PMC: 10804850. DOI: 10.3389/fimmu.2023.1307228.

Hitting the Sweet Spot: How Glucose Metabolism Is Orchestrated in Space and Time by Phosphofructokinase-1.

Campos M, Albrecht L Cancers (Basel). 2024; 16(1).

PMID: 38201444 PMC: 10778546. DOI: 10.3390/cancers16010016.

Human Triosephosphate Isomerase Is a Potential Target in Cancer Due to Commonly Occurring Post-Translational Modifications.

Enriquez-Flores S, de la Mora-de la Mora I, Garcia-Torres I, Flores-Lopez L, Martinez-Perez Y, Lopez-Velazquez G Molecules. 2023; 28(16).

PMID: 37630415 PMC: 10459230. DOI: 10.3390/molecules28166163.

References

Fumet J, Truntzer C, Yarchoan M, Ghiringhelli F . Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. Eur J Cancer. 2020; 131:40-50. PMC: 9473693. DOI: 10.1016/j.ejca.2020.02.038. View

Cui X, Zhang X, Liu M, Zhao C, Zhang N, Ren Y . A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors. Genomics. 2020; 112(6):3958-3967. DOI: 10.1016/j.ygeno.2020.06.044. View

Wang C, Qu J, Yan S, Gao Q, Hao S, Zhou D . PFK15, a PFKFB3 antagonist, inhibits autophagy and proliferation in rhabdomyosarcoma cells. Int J Mol Med. 2018; 42(1):359-367. PMC: 5979828. DOI: 10.3892/ijmm.2018.3599. View

Chen D, Ning W, Jiang Z, Peng Z, Zhu L, Zhuang S . Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. J Hepatol. 2019; 71(2):333-343. DOI: 10.1016/j.jhep.2019.04.007. View

Vander Heiden M, Cantley L, Thompson C . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. PMC: 2849637. DOI: 10.1126/science.1160809. View

Ru B, Wong C, Tong Y, Zhong J, Zhong S, Wu W . TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019; 35(20):4200-4202. DOI: 10.1093/bioinformatics/btz210. View

Liu C, Hu F, Xia M, Han L, Zhang Q, Guo A . GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018; 34(21):3771-3772. DOI: 10.1093/bioinformatics/bty411. View

Williams N, ONeill L . A Role for the Krebs Cycle Intermediate Citrate in Metabolic Reprogramming in Innate Immunity and Inflammation. Front Immunol. 2018; 9:141. PMC: 5807345. DOI: 10.3389/fimmu.2018.00141. View

Yalcin A, Clem B, Simmons A, Lane A, Nelson K, Clem A . Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. J Biol Chem. 2009; 284(36):24223-32. PMC: 2782016. DOI: 10.1074/jbc.M109.016816. View

10.

Wang Y, Nie H, Liao Z, He X, Xu Z, Zhou J . Expression and Clinical Significance of Lactate Dehydrogenase A in Colon Adenocarcinoma. Front Oncol. 2021; 11:700795. PMC: 8300199. DOI: 10.3389/fonc.2021.700795. View

11.

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

12.

Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y . Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005; 65(3):999-1006. View

13.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

14.

Peng Z, Jiang Z, Guo H, Zhou M, Huang Y, Ning W . Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma. J Hepatol. 2020; 73(4):906-917. DOI: 10.1016/j.jhep.2020.05.004. View

15.

Zhao L, Wang B, Yang C, Lin Y, Zhang Z, Wang S . TDO2 knockdown inhibits colorectal cancer progression via TDO2-KYNU-AhR pathway. Gene. 2021; 792:145736. DOI: 10.1016/j.gene.2021.145736. View

16.

Mittal V . Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018; 13:395-412. DOI: 10.1146/annurev-pathol-020117-043854. View

17.

Kotowski K, Rosik J, Machaj F, Supplitt S, Wiczew D, Jablonska K . Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets. Cancers (Basel). 2021; 13(4). PMC: 7926708. DOI: 10.3390/cancers13040909. View

18.

Liu Z, Zhou Q, Wang Z, Zhang H, Zeng H, Huang Q . Intratumoral TIGIT CD8 T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. J Immunother Cancer. 2020; 8(2). PMC: 7430558. DOI: 10.1136/jitc-2020-000978. View

19.

Gustafsson N, Farnegardh K, Bonagas N, Ninou A, Groth P, Wiita E . Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination. Nat Commun. 2018; 9(1):3872. PMC: 6155239. DOI: 10.1038/s41467-018-06287-x. View

20.

Tang Z, Kang B, Li C, Chen T, Zhang Z . GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019; 47(W1):W556-W560. PMC: 6602440. DOI: 10.1093/nar/gkz430. View